Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Sumiyoshi, T. Articles by Meltzer, H. Y. Search for Related Content PubMed Citation Articles by Sumiyoshi, T. Articles by Meltzer, H. Y. Schizophrenia Spectrum Disorders Other Neuroleptics Cognition

Enhancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment

OBJECTIVE: The goal of this study was to evaluate the effects of the addition of tandospirone, a serotonin-1A (5-HT_1A) agonist, to ongoing treatment with typical antipsychotic drugs, on two cognitive domains that are relevant to functional outcome in patients with schizophrenia. METHOD: Twenty-six patients with schizophrenia who were receiving stable doses of typical antipsychotics were randomly assigned to adjunctive treatment with 30 mg/day of tandospirone or placebo for 6 weeks. Executive function and verbal memory as well as psychopathology were assessed at baseline and after 6 weeks. RESULTS: Both cognitive measures improved significantly in the patients who received tandospirone; subjects who did not receive tandospirone showed no change. There was no significant change in psychopathology ratings in either group. CONCLUSIONS: The results suggest the usefulness of 5-HT_1A agonists for enhancing some types of cognitive performance and possibly social and work function in patients with schizophrenia.

This article has been cited by other articles:

				L Dahan, H Husum, O Mnie-Filali, J Arnt, P Hertel, and N Haddjeri Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour J Psychopharmacol, March 1, 2009; 23(2): 177 - 189. [Abstract] [PDF]

				J. A. Gray and B. L. Roth Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119. [Abstract] [Full Text] [PDF]

				S. R. Chamberlain, U. Muller, J. B. Deakin, P. R. Corlett, J. Dowson, R. N. Cardinal, M. R. F. Aitken, T. W. Robbins, and B. J. Sahakian Lack of deleterious effects of buspirone on cognition in healthy male volunteers J Psychopharmacol, March 1, 2007; 21(2): 210 - 215. [Abstract] [PDF]

				J. J Hagan and D. N C Jones Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia Schizophr Bull, October 1, 2005; 31(4): 830 - 853. [Abstract] [Full Text] [PDF]

				R. A. Bantick, A. J. Montgomery, C. J. Bench, T. Choudhry, N. Malek, P. J. McKenna, D. J. Quested, J. F. W. Deakin, and P. M. Grasby A Positron Emission Tomography Study of the 5-Ht1A Receptor in Schizophrenia and during Clozapine Treatment J Psychopharmacol, September 1, 2004; 18(3): 346 - 354. [Abstract] [PDF]

				T. SUMIYOSHI and H. Y. MELTZER Serotonin 1A Receptors in Memory Function Am J Psychiatry, August 1, 2004; 161(8): 1505 - 1505. [Full Text] [PDF]

				F. Yasuno, T. Suhara, T. Nakayama, T. Ichimiya, Y. Okubo, A. Takano, T. Ando, M. Inoue, J. Maeda, and K. Suzuki Inhibitory Effect of Hippocampal 5-HT1A Receptors on Human Explicit Memory Am J Psychiatry, February 1, 2003; 160(2): 334 - 340. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us